Primary biliary cirrhosis: Lessons learned from an organ-specific disease

Clinical and Experimental Medicine

Volumn 1, Issue 4, 2001, Pages 165-178

  Nishio, A ^a   Keeffe, E B ^b   Gershwin, M E ^c  

^a TENRI HOSPITAL   (Japan)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antimitochondrial antibodies; Autoimmunity; Cholestatic liver disease; Primary biliary cirrhosis

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AUTOANTIBODY; CHLORAMBUCIL; CYCLOSPORIN; EPITOPE; GAMMA GLUTAMYLTRANSFERASE; MITOCHONDRION ANTIBODY; OXIDOREDUCTASE; PREDNISOLONE; URSODEOXYCHOLIC ACID;

ANTIBODY SPECIFICITY; ASCITES; AUTOIMMUNE DISEASE; BILE DUCT INJURY; BLEEDING; BRAIN DISEASE; CHOLESTASIS; CLINICAL FEATURE; CYTOTOXICITY; DISEASE COURSE; DISEASE PREDISPOSITION; ENZYME BLOOD LEVEL; FIBROSIS; HUMAN; INFLAMMATION; LIVER BIOPSY; LIVER TRANSPLANTATION; MITOCHONDRION; PATHOGENESIS; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SEROLOGY; SYMPTOMATOLOGY; T LYMPHOCYTE;

EID: 0035727934     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s102380100000     Document Type: Review

References (79)

1. On a certain affection of the skin-vitiligoidea alpha plana, beta tuberosa
2. Primary biliary cirrhosis
3. Primary biliary cirrhosis showing a high titer of autoantibody: Report of a case
4. Serological tests in diagnosis of primary biliary cirrhosis
5. Low prevalence of primary biliary cirrhosis in Victoria, Australia
6. The epidemiology of primary biliary cirrhosis in North-east England: An increasingly common disease?
7. Primary biliary cirrhosis: An epidemiological study
8. Familial primary biliary cirrhosis reassessed: A geographically-based population study
9. High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis
10. Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis
11. Primary biliary cirrhosis: Contribution of HLA class II allele DR8
12. Major histocompatibility complex class II-alleles in primary biliary cirrhosis
13. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis
14. Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region
15. Tumour necrosis factor-α promoter polymorphisms in primary biliary cirrhosis
16. No evidence for involvement of the interleukin-10-592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis
17. Primary biliary cirrhosis
18. Antimitochondrial antibodies in primary biliary cirrhosis
19. Primary structure of the human M2 mitochondrial autoantigen of primary cirrhosis: Dihydrolipoamide acetyltransferase
20. Identification and specificity of a cDNA encoding the 70kD mitochondrial antigen recognized in primary biliary cirrhosis
21. Primary biliary cirrhosis: Identification of two major M2 mitochondrial autoantigens
22. Antimitochondrial antibodies of primary biliary cirrhosis recognize dihy-drolipoamide acyltransferase and inhibit enzyme function of the branched chain α-ketoacid dehydrogenase complex
23. Inhibition of α-ketoglutarate dehy-drogenase activity by a distinct population of autoantibodies recognizing dihydrolipoamide succinyltransferase in primary biliary cirrhosis
24. Primary biliary cirrhosis: Inhibition of pyruvate dehy-drogenase complex activity by autoantibodies specific for E1α, a non-lipoic acid containing mitochondrial enzyme
25. Reactivity of primary biliary cirrhosis sera with a human fetal liver cDNA clone of branched-chain α-keto acid dehydrogenase dihydrolipoamide acyltransferase, the 52 kD mitochondrial autoantigen
26. Antimitochondrial autoantibodies in primary biliary cirrhosis recognize cross-reactive epitope(s) on protein X and dihy-drolipoamide acetyltransferase of pyruvate dehydrogenase complex
27. Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function
28. Structural requirement for autoreactivity on human pyruvate dehydrogenase-E2, the major autoantigen of primary biliary cirrhosis Implication for a conformational autoepitope
29. Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3BP) and the glycine cleavage proteins in primary biliary cirrhosis
30. Autoantibodies to BCOADC-E2 in patients with primary biliary cirrhosis recognize a conformational epitope
31. Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex
32. Reactivity of primary biliary cirrhosis sera with Escherichia coli dihydrolipoamide acetyltransferase (E2p): Characterization of the main immunogenic region
33. Site-directed mutagenesis of lysine within the immunodominant autoepitope of PDC-E2
34. Lipoylated and unlipoylated domains of human PDC-E2 as autoantigens in primary biliary cirrhosis: Significance of lipoate attachment
35. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis
36. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis
37. Autoimmune sera recognize a 100 kD nuclear protein antigen (sp-100)
38. Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis
39. Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis
40. Distribution of dihy-drolipoamide acetyltransferase (E2) in the liver and portal lymph nodes of patients with primary biliary cirrhosis: An immunohistochemical study
41. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2
42. Monoclonal antibodies to mitochondrial E2 components define autoepitopes in primary biliary cirrhosis
43. In situ nucleic acid detection of PDC-E2, BCOADC-E2, OGDC-E2, PDC-E1α, BCOADC-E1α, OGDC-E1, and the E3 binding protein (protein X) in primary biliary cirrhosis
44. Heterogeneous response of antimitochondrial autoantibodies and bile duct apical staining monoclonal antibodies to pyruvate dehydrogenase complex E2: The molecule versus the mimic
45. Comparative studies of antimitochondrial autoantibodies in sera and bile in primary biliary cirrhosis
46. Primary biliary cirrhosis is a dry gland syndrome with features of chronic graft-versus-host disease
47. Human combinatorial autoantibodies and mouse monoclonal antibodies to PDC-E2 produce abnormal apical staining of salivary glands in patients with coexistent primary biliary cirrhosis and Sjögren's syndrome
48. Evidence for a locally driven mucosal response and the presence of mitochondrial antigens in saliva in primary biliary cirrhosis
49. Analysis of hepatic T lymphocyte and immunoglobulin deposits in patients with primary biliary cirrhosis
50. Evidence for the targeting by 2-oxo-dehydrogenase enzymes in the T-cell response of primary biliary cirrhosis
51. HLA DRB4 0101-restricted immunodominant T-cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: Evidence of molecular mimicry in human autoimmune diseases
52. Identification and precursor frequency analysis of a common T-cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis
53. Aberrant expression of HLA-DR antigens on bile duct epithelium in primary biliary cirrhosis: Relevance to pathogenesis
54. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases Practice Guidelines
55. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration
56. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy
57. Immunomodulatory effects of ursodeoxycholic acid on immune responses
58. Nuclear DNA fragmentation and expression of bcl-2 in primary biliary cirrhosis
59. Molecular aspects of membrane stabilization by ursodeoxycholate
60. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis
61. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
62. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
63. Ursodeoxycholic acid in the treatment of biliary cirrhosis
64. Ursodiol for the long-term treatment of primary biliary cirrhosis
65. Characterization of patients with a complete biochemical response to ursodeoxycholic acid
66. Randomized controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: A meta-analysis
67. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis
68. Bezafibrate in the treatment of primary biliary cirrhosis: Comparison with ursodeoxycholic acid
69. Prognosis in primary biliary cirrhosis: Model for decision making
70. Quality of life before and after liver transplantation for cholestatic liver disease
71. Recurrence of primary biliary cirrhosis after liver transplantation
72. A controlled trial of naloxone infusions for the pruritus of cholestasis
73. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: Preliminary results after 2 years
74. Fat-soluble vitamin nutriture in primary biliary cirrhosis
75. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: What is the risk?
76. Primary biliary cirrhosis: Survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years
77. A symptomatic primary biliary cirrhosis: A study of its natural history and prognosis
78. Serum bilirubin: A prognostic factor in primary biliary cirrhosis
79. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis. The American Association for the Study of Liver Diseases Practice Guidelines